|Circos: an information aesthetic for comparative genomics|
M Krzywinski, J Schein, I Birol, J Connors, R Gascoyne, D Horsman, ...
Genome research 19 (9), 1639-1645, 2009
|Revised response criteria for malignant lymphoma|
BD Cheson, B Pfistner, ME Juweid, RD Gascoyne, L Specht, SJ Horning, ...
Journal of clinical oncology 25 (5), 579-586, 2007
|Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray|
CP Hans, DD Weisenburger, TC Greiner, RD Gascoyne, J Delabie, G Ott, ...
Blood 103 (1), 275-282, 2004
|The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma|
A Rosenwald, G Wright, WC Chan, JM Connors, E Campo, RI Fisher, ...
New England Journal of Medicine 346 (25), 1937-1947, 2002
|Stromal gene signatures in large-B-cell lymphomas|
G Lenz, G Wright, SS Dave, W Xiao, J Powell, H Zhao, W Xu, B Tan, ...
New England Journal of Medicine 359 (22), 2313-2323, 2008
|Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin|
RD Morin, NA Johnson, TM Severson, AJ Mungall, J An, R Goya, JE Paul, ...
Nature genetics 42 (2), 181-185, 2010
|Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma|
RE Davis, VN Ngo, G Lenz, P Tolar, RM Young, PB Romesser, ...
Nature 463 (7277), 88-92, 2010
|Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma|
RD Morin, M Mendez-Lago, AJ Mungall, R Goya, KL Mungall, RD Corbett, ...
Nature 476 (7360), 298-303, 2011
|Oncogenically active MYD88 mutations in human lymphoma|
VN Ngo, RM Young, R Schmitz, S Jhavar, W Xiao, KH Lim, ...
Nature 470 (7332), 115-119, 2011
|Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma|
TM Habermann, EA Weller, VA Morrison, RD Gascoyne, PA Cassileth, ...
Journal of clinical oncology 24 (19), 3121-3127, 2006
|The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP|
LH Sehn, B Berry, M Chhanabhai, C Fitzgerald, K Gill, P Hoskins, R Klasa, ...
Blood 109 (5), 1857-1861, 2007
|Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells|
SS Dave, G Wright, B Tan, A Rosenwald, RD Gascoyne, WC Chan, ...
New England Journal of Medicine 351 (21), 2159-2169, 2004
|Genetics and pathogenesis of diffuse large B-cell lymphoma|
R Schmitz, GW Wright, DW Huang, CA Johnson, JD Phelan, JQ Wang, ...
New England Journal of Medicine 378 (15), 1396-1407, 2018
|Tumor-associated macrophages and survival in classic Hodgkin's lymphoma|
C Steidl, T Lee, SP Shah, P Farinha, G Han, T Nayar, A Delaney, ...
New England Journal of Medicine 362 (10), 875-885, 2010
|Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma|
A Rosenwald, G Wright, K Leroy, X Yu, P Gaulard, RD Gascoyne, ...
The Journal of experimental medicine 198 (6), 851-862, 2003
|Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia|
LH Sehn, J Donaldson, M Chhanabhai, C Fitzgerald, K Gill, R Klasa, ...
Journal of clinical oncology 23 (22), 5027-5033, 2005
|Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways|
G Lenz, GW Wright, NCT Emre, H Kohlhammer, SS Dave, RE Davis, ...
Proceedings of the National Academy of Sciences 105 (36), 13520-13525, 2008
|Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma|
MP Chao, AA Alizadeh, C Tang, JH Myklebust, B Varghese, S Gill, M Jan, ...
Cell 142 (5), 699-713, 2010
|Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone|
NA Johnson, GW Slack, KJ Savage, JM Connors, S Ben-Neriah, S Rogic, ...
Journal of clinical oncology 30 (28), 3452, 2012
|The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma|
A Rosenwald, G Wright, A Wiestner, WC Chan, JM Connors, E Campo, ...
Cancer cell 3 (2), 185-197, 2003